A new, rapid, selective, green, and highly sensitive method has been established to determine ivabradine and carvedilol simultaneously. The first derivative synchronous spectrofluorimetric approach was applied for the determination of the studied drugs. Assessment of the first derivative amplitude of carvedilol and ivabradine has been done at 339 nm and 298 nm respectively which are the zero crossing points of each other. The method validation is estimated and was found to be consistent with International Conference on Harmonization guidelines. Linearity was found to be in the range of 10.0 to 90.0 ng/mL for carvedilol and from 80.0 to140.0 ng/mL for ivabradine. The detection limits were found to be 1.2 ng/ mL and 3.3 ng/mL and the quantitation limits were 3.7 ng / mL and 10.0 ng /mL for carvedilol and ivabradine, respectively. The method was effectively applied for the determination of both drugs in their synthetic mixture in different ratios and in their prepared co-formulated tablets. The results were compared with those of comparison HPLC methods. Ethanol was used as a green solvent. The proposed method is suitable for the determination of ivabradine and carvedilol with satisfactory accuracy and precision. The greenness of the method was evaluated using four assessment tools, i.e. NEMI, GAPI, Eco-scale, and AGREE. The proposed method is simple with a low cost compared to HPLC methods.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.saa.2022.122074 | DOI Listing |
BMC Cardiovasc Disord
September 2024
Department of Cardiology, Niigata City General Hospital, 463-7, Shumoku, Chuo-ku, Niigata, 950-1197, Japan.
Cureus
February 2024
Pharmacology and Therapeutics, Ruxmaniben Deepchand Gardi Medical College, Ujjain, IND.
Background The elderly population differs from adults in having various physiological changes and multiple diseases, which demand the use of multiple medications. The practice of polypharmacy in the elderly leads to numerous harmful effects like adverse drug reactions, adverse drug-drug interactions (DDIs), poor compliance, etc. Methodology This study collected 295 case files of elderly patients retrospectively in the Departments of General Medicine, Cardiology and Nephrology after obtaining Institute Ethics Committee approval to look for the potential adverse DDIs with their severity according to the clinical significance.
View Article and Find Full Text PDFEur Heart J Case Rep
January 2024
Department of Cardiovascular Medicine, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-dori, Chuo-ku, Niigata-city 951-8520, Japan.
Background: Pulsus alternans has been considered a sign of poor prognosis in patients undergoing treatments for heart failure. However, it may be overlooked in patients with intra-aortic balloon pumps (IABPs). The use of IABP and ivabradine for a β-blocker introduction in a patient with dilated cardiomyopathy (DCM) and pulsus alternans and its consequence have never been reported.
View Article and Find Full Text PDFESC Heart Fail
February 2024
School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
Background: Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta-blockers. Degenerative mitral regurgitation (MR) is a valvular heart disease often associated with the development of HF and atrial fibrillation (AF).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!